A
Alcista
Alcista · 25%EBS
$7.49
Precio del escenario
$6.360
-0.020 (-0.31%)Al cierre
Loading chart…
- Máximo
- 6.579
- Apertura
- 6.400
- Precio medio ponderado por volumen
- 6.43
- Volumen
- 817.33K
- Capitalización
- 365.76M
- Mínimo
- 6.350
- Importe
- 5.26M
- EV/EBITDA, TTM
- 2.76
Emergent BioSolutions, Inc. is a life sciences company. It is focused on providing preparedness and response solutions addressing accidental, deliberate and naturally occurring public health threats. Its solutions include a product portfolio, a product development portfolio, and a contract development and manufacturing services portfolio. Its segments include Commercial Products, MCM Products, and Services segment. Its Commercial Product segment consists of NARCAN Nasal Spray. Its MCM Products segment consists of Anthrax MCM products, Smallpox MCM products and Other Products. Its Services segment consists of its Bioservices portfolio. NARCAN (naloxone HCl) Nasal Spray, an intranasal formulation of naloxone, is developed for the emergency treatment of known or suspected opioid overdose as manifested by respiratory and central nervous system depression. Its Bioservices consist of development services, bulk drug substance manufacturing, fill, finish, and packaging of final drug products.
Análisis de IA of Emergent BioSolutions Inc (EBS)
VenderEmergent BioSolutions Inc is not a good buy right now due to significant financial losses and bearish market sentiment. The current price is $6.38, and the company reported a staggering net loss of $180.2 million in Q2 2026, which has led to a year-to-date decline of 49%. Furthermore, insider selling has increased by 140.86%, indicating a lack of confidence from those closest to the company.
Recomendaciones de analistas (6)
+135.85% de potencial alcista
Comprar
5 Comprar
1 Mantener
0 Vender
Actual: 6.36
Mínimo
15.00
Promedio
15.00
Máximo
15.00
JPMorgan
Infraponderar
—
2026-08-21
JPMorgan
2026-08-21
Precio objetivo
—
Infraponderar
H.C. Wainwright
Comprar
$10
2026-08-10
H.C. Wainwright
2026-08-10
Precio objetivo
$10
Comprar
H.C. Wainwright
Comprar
$12
2026-03-09
H.C. Wainwright
2026-03-09
Precio objetivo
$12
Comprar
JPMorgan
Sobreponderar
—
2025-12-02
JPMorgan
2025-12-02
Precio objetivo
—
Sobreponderar
Barclays
Sobreponderar
—
2025-12-02
Barclays
2025-12-02
Precio objetivo
—
Sobreponderar
Métricas de valoración
El PER previsto actual de Emergent BioSolutions Inc (EBS) es 22.99, frente a su media de 5 años de 13.19.
Escenarios de precio de Alphio AI para EBS
Los precios por escenario son la última banda de previsión mensual del año en curso. Las probabilidades son pesos fijos del modelo (25 / 50 / 25), no garantías.
Cronología de eventos
Noticias
2.010-06stocktwitsRussian Plague Scare Triggers Vaccine Stock Surge
7.009-24PRnewswirePomerantz LLP Investigates Securities Fraud Claims Against Emergent BioSolutions
7.008-27PRnewswireEmergent BioSolutions Under Investigation for Securities Fraud
7.008-19NewsfilterEmergent BioSolutions Under Investigation for Securities Violations
- 7.008-17Newsfilter
Emergent BioSolutions Under Investigation for Securities Violations
Preguntas frecuentes sobre EBS, respondidas por Alphio AI
Emergent BioSolutions, Inc. is a life sciences company. It is focused on providing preparedness and response solutions addressing accidental, deliberate and naturally occurring public health threats. Its solutions include a product portfolio, a product development portfolio, and a contract development and manufacturing services portfolio. Its segments include Commercial Products, MCM Products, and Services segment. Its Commercial Product segment consists of NARCAN Nasal Spray. Its MCM Products segment consists of Anthrax MCM products, Smallpox MCM products and Other Products. Its Services segment consists of its Bioservices portfolio. NARCAN (naloxone HCl) Nasal Spray, an intranasal formulation of naloxone, is developed for the emergency treatment of known or suspected opioid overdose as manifested by respiratory and central nervous system depression. Its Bioservices consist of development services, bulk drug substance manufacturing, fill, finish, and packaging of final drug products. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).
Emergent BioSolutions Inc is not a good buy right now due to significant financial losses and bearish market sentiment. The current price is $6.38, and the company reported a staggering net loss of $180.2 million in Q2 2026, which has led to a year-to-date decline of 49%. Furthermore, insider selling has increased by 140.86%, indicating a lack of confidence from those closest to the company.
6 analysts cover EBS: 5 rate it Buy, 1 Hold and 0 Sell. The average price target is 15.00.
Comunidad
Más ↗Aún no hay publicaciones
Regístrate o inicia sesión para participarEsta página es solo para investigación y no constituye asesoramiento de inversión. Los modelos pueden equivocarse. El rendimiento pasado no garantiza resultados futuros.